Pulmonary Pharmacology & Therapeutics

Pulmonary Pharmacology & Therapeutics is published by Academic Press Inc. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Asthma and respiratory diseases, Respiratory and Cough-Related Research and Chronic Obstructive Pulmonary Disease (COPD) Research, together about 45.4% of its articles. Its main subfields are Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)

Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews.Research Areas Include:• All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary ToxicologyBefore submitting, please note the "Rules of 5" defining immediate rejection criteria of PPT:1. Out of scope: The paper should report on the use of pharmacological or toxicological studies (positive or negative) that are directly related to Pulmonary Pharmacology & Therapeutics.Immediate rejection criteria are: a) Testing of extracts or plant parts that are not characterized b) Case Reports or n=1 studies2. Too preliminary: A paper must be based on a thorough and extensive study, using proper controlsImmediate rejection criteria are: a) In vitro studies with a single dose, or very high concentration b) Single dose studies with very few animals, no dose-response studies c) No proper controls. d) Repetition or confirmation of an earlier work3. Unethical: The study must have been carried under appropriate ethical approval for the study (either animal or human).4. Inappropriate experiments or lacking essential detailImmediate rejection criteria are: a) Wrong species or lacking details on the exact number of animals/subjects used b) No details of structure if a new drug is used for the first time5. Lack of novelty: The study must represent a novel approach to the field.Immediate rejection criteria are: a) Repetition of well known data b) No advance of knowledge in the fieldNote that only manuscripts written in good English will be considered by the Editors (British usage is preferred).

From the journal's Aims & Scope

Research area (LetPub): Respiratory System

Editor-in-chief Estelle Cormet-BoyakaPublisher website

Editorial board by country: 1 in mainland China (about 3%); most named United States 12, United Kingdom 8, Italy 7, Singapore 2, Mainland China 1 (35 members with a country) Editorial board ↗Publisher website · 2026-10-01

CAS Journal Ranking

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

3.61LetPub · 2026-09-13

Impact factor (publisher)

3.8Publisher website · 2026-10-01

CiteScore 2026-06

5.9LetPub · 2026-09-13

CiteScore (publisher)

5.9Publisher website · 2026-10-01

SJR 2026-06

0.82LetPub · 2026-09-13

SNIP 2026-06

0.77LetPub · 2026-09-13

h-index

66LetPub · 2026-09-13

h-index

95OpenAlex · 2026-10-01

i10-index

1,440OpenAlex · 2026-10-01

2-year mean citedness

3.27OpenAlex · 2026-10-01

Self-citation rate

2.6%LetPub · 2026-09-13

Share of gold OA articles

20.79%LetPub · 2026-09-13

Volume

Articles per year

26LetPub · 2026-09-13

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

6–12 weeksLetPub · 2026-09-13

Average acceptance (community reports)

Fairly easyLetPub · 2026-09-13

Submission to first decision

16 daysPublisher website · 2026-10-01

First decision after review

85 daysPublisher website · 2026-10-01

Submission to acceptance

131 daysPublisher website · 2026-10-01

Acceptance to publication

2 daysPublisher website · 2026-10-01

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Academic Press Inc.

Country or region

ENGLAND

Language

English

Frequency

Bimonthly

Founded

1997

ISSN

1094-5539

Electronic ISSN

1522-9629

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗Publisher website
• Special issues ↗Publisher website